PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
Abstract Objectives To describe PSMA PET/CT characteristics of patients with high‐risk BCR. Subjects/patients and methods This was a retrospective analysis of patients with high‐risk BCR prostate cancer (PSA ≥ 2 ng/ml above nadir after radiation therapy [RT] or ≥1 ng/ml after radical prostatectomy [...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.70028 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849762057572843520 |
|---|---|
| author | Nicole Handa Richard Bennett IV Eric V. Li Austin Ho Mitchell M. Huang Sai Kumar Clayton Neill Ridwan Alam Hiten D. Patel Edward M. Schaeffer Ashley E. Ross |
| author_facet | Nicole Handa Richard Bennett IV Eric V. Li Austin Ho Mitchell M. Huang Sai Kumar Clayton Neill Ridwan Alam Hiten D. Patel Edward M. Schaeffer Ashley E. Ross |
| author_sort | Nicole Handa |
| collection | DOAJ |
| description | Abstract Objectives To describe PSMA PET/CT characteristics of patients with high‐risk BCR. Subjects/patients and methods This was a retrospective analysis of patients with high‐risk BCR prostate cancer (PSA ≥ 2 ng/ml above nadir after radiation therapy [RT] or ≥1 ng/ml after radical prostatectomy [RP] +/− RT) who underwent PET/CT from July 2021–March 2023. Patients with prior cytotoxic chemotherapy, androgen deprivation therapy (ADT) initiated >3 months prior to PET/CT or positive conventional imaging within 3 months of PET/CT were excluded. Neoadjuvant/adjuvant ADT completed ≥9 months prior was allowed. Logistic regression, Pearson's Chi‐squared, Wilcoxon rank sum and Fisher's exact tests were used for analysis. Results A total of 113 of 145 (77%) included patients in the analysis had ≥1 lesion on PSMA PET/CT. There was no difference in PSMA PET/CT positivity based on age, race, Gleason Grade at initial biopsy or PSA. Overall, 29 (20%) patients had lesions in the prostate/prostate bed only, 31 (21%) had lesions consistent with N1M0 disease and 53 (37%) had lesions consistent with M1 disease. For M1 patients, 21/53 (40%) had oligometastatic disease (1–3 lesions), and 32/53 (60%) had a higher burden (>3 lesions). Local recurrence was more common with RT and nodal recurrence with RP, with no difference in distant metastasis by initial treatment. Conclusion Nearly 80% of patients with high‐risk BCR after local treatment for prostate cancer with RP and/or RT will have positive findings on PSMA PET/CT. In addition to intensified systemic therapy, up to 55% of the patients may have benefitted from salvage local therapy, nodal pelvic radiation or metastasis‐directed therapies for oligometastatic disease. |
| format | Article |
| id | doaj-art-cf93afd405024da8976cb677c0188cae |
| institution | DOAJ |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-cf93afd405024da8976cb677c0188cae2025-08-20T03:05:50ZengWileyBJUI Compass2688-45262025-05-0165n/an/a10.1002/bco2.70028PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancerNicole Handa0Richard Bennett IV1Eric V. Li2Austin Ho3Mitchell M. Huang4Sai Kumar5Clayton Neill6Ridwan Alam7Hiten D. Patel8Edward M. Schaeffer9Ashley E. Ross10Northwestern University, Feinberg School of Medicine Chicago IL USAIndiana University School of Medicine Indianapolis IN USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USANorthwestern University, Feinberg School of Medicine Chicago IL USAAbstract Objectives To describe PSMA PET/CT characteristics of patients with high‐risk BCR. Subjects/patients and methods This was a retrospective analysis of patients with high‐risk BCR prostate cancer (PSA ≥ 2 ng/ml above nadir after radiation therapy [RT] or ≥1 ng/ml after radical prostatectomy [RP] +/− RT) who underwent PET/CT from July 2021–March 2023. Patients with prior cytotoxic chemotherapy, androgen deprivation therapy (ADT) initiated >3 months prior to PET/CT or positive conventional imaging within 3 months of PET/CT were excluded. Neoadjuvant/adjuvant ADT completed ≥9 months prior was allowed. Logistic regression, Pearson's Chi‐squared, Wilcoxon rank sum and Fisher's exact tests were used for analysis. Results A total of 113 of 145 (77%) included patients in the analysis had ≥1 lesion on PSMA PET/CT. There was no difference in PSMA PET/CT positivity based on age, race, Gleason Grade at initial biopsy or PSA. Overall, 29 (20%) patients had lesions in the prostate/prostate bed only, 31 (21%) had lesions consistent with N1M0 disease and 53 (37%) had lesions consistent with M1 disease. For M1 patients, 21/53 (40%) had oligometastatic disease (1–3 lesions), and 32/53 (60%) had a higher burden (>3 lesions). Local recurrence was more common with RT and nodal recurrence with RP, with no difference in distant metastasis by initial treatment. Conclusion Nearly 80% of patients with high‐risk BCR after local treatment for prostate cancer with RP and/or RT will have positive findings on PSMA PET/CT. In addition to intensified systemic therapy, up to 55% of the patients may have benefitted from salvage local therapy, nodal pelvic radiation or metastasis‐directed therapies for oligometastatic disease.https://doi.org/10.1002/bco2.70028biochemical recurrencediagnosticsoligometastatic diseaseprostate cancerPSMA PET/CT |
| spellingShingle | Nicole Handa Richard Bennett IV Eric V. Li Austin Ho Mitchell M. Huang Sai Kumar Clayton Neill Ridwan Alam Hiten D. Patel Edward M. Schaeffer Ashley E. Ross PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer BJUI Compass biochemical recurrence diagnostics oligometastatic disease prostate cancer PSMA PET/CT |
| title | PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer |
| title_full | PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer |
| title_fullStr | PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer |
| title_full_unstemmed | PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer |
| title_short | PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer |
| title_sort | psma pet ct findings in high risk biochemical recurrence after local treatment of prostate cancer |
| topic | biochemical recurrence diagnostics oligometastatic disease prostate cancer PSMA PET/CT |
| url | https://doi.org/10.1002/bco2.70028 |
| work_keys_str_mv | AT nicolehanda psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT richardbennettiv psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT ericvli psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT austinho psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT mitchellmhuang psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT saikumar psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT claytonneill psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT ridwanalam psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT hitendpatel psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT edwardmschaeffer psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer AT ashleyeross psmapetctfindingsinhighriskbiochemicalrecurrenceafterlocaltreatmentofprostatecancer |